Evidence map›Paper›PMID 38557758›Full record

ArticlePloS one2024

COVID-related disruptions to colorectal cancer screening, diagnosis, and treatment could increase cancer Burden in Australia and Canada: A modelling study.

Joachim Worthington, Zhuolu Sun, Rui Fu, Jie-Bin Lew, Kelvin K W Chan, Qing Li, Antoine Eskander, Harriet Hui, Kirstie McLoughlin, Michael Caruana and 5 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in PloS one, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors.

Joachim WorthingtonThe Daffodil Centre, Kings Cross, New South Wales, Australia.ORCID 0000-0002-8830-0520
Zhuolu SunCanadian Partnership Against Cancer, Toronto, ON, Canada.
Rui FuICES, Toronto, Ontario, Canada.ORCID 0000-0002-0577-2830
Jie-Bin LewThe Daffodil Centre, Kings Cross, New South Wales, Australia.
Kelvin K W ChanInstitute of Health Policy, Management and Evaluation, Dalla Lana School of Public Health, University of Toronto, Toronto, Ontario, Canada.
Qing LiICES, Toronto, Ontario, Canada.
Antoine EskanderICES, Toronto, Ontario, Canada.ORCID 0000-0003-4326-1393
Harriet HuiThe Daffodil Centre, Kings Cross, New South Wales, Australia.
Kirstie McLoughlinThe Daffodil Centre, Kings Cross, New South Wales, Australia.
Michael CaruanaThe Daffodil Centre, Kings Cross, New South Wales, Australia.
Stuart PeacockFaculty of Health Sciences, Simon Fraser University, Burnaby, BC, Canada.
Jean Hai Ein YongCanadian Partnership Against Cancer, Toronto, ON, Canada.
Karen CanfellThe Daffodil Centre, Kings Cross, New South Wales, Australia.
Eleonora FelettoThe Daffodil Centre, Kings Cross, New South Wales, Australia.
Talía MalagónDepartment of Oncology, McGill University, Montréal, Canada.ORCID 0000-0002-9505-3564

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

COVID-19 disrupted cancer control worldwide, impacting preventative screening, diagnoses, and treatment services. This modelling study estimates the impact of disruptions on colorectal cancer cases and deaths in Canada and Australia, informed by data on screening, diagnosis, and treatment procedures. Modelling was used to estimate short- and long-term effects on colorectal cancer incidence and mortality, including ongoing impact of patient backlogs. A hypothetical mitigation strategy was simulated, with diagnostic and treatment capacities increased by 5% from 2022 to address backlogs. Colorectal cancer screening dropped by 40% in Canada and 6.3% in Australia in 2020. Significant decreases to diagnostic and treatment procedures were also observed in Australia and Canada, which were estimated to lead to additional patient wait times. These changes would lead to an estimated increase of 255 colorectal cancer cases and 1,820 colorectal cancer deaths in Canada and 234 cases and 1,186 deaths in Australia over 2020-2030; a 1.9% and 2.4% increase in mortality, respectively, vs a scenario with no screening disruption or diagnostic/treatment delays. Diagnostic and treatment capacity mitigation would avert 789 and 350 deaths in Canada and Australia, respectively. COVID-related disruptions had a significant impact on colorectal cancer screening, diagnostic, and treatment procedures in Canada and Australia. Modelling demonstrates that downstream effects on disease burden could be substantial. However, backlogs can be managed and deaths averted with even small increases to diagnostic and treatment capacity. Careful management of resources can improve patient outcomes after any temporary disruption, and these results can inform targeted approaches early detection of cancers.

Indexed as

Colorectal NeoplasmsCOVID-19AustraliaCanadaCOVID-19 TestingEarly Detection of CancerHumans

Identifiers

PMID38557758
PMCPMC10984523

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.